7 min. read

Genentech-Roche VR for autism. FDA’s new remote monitoring waiver.

Issue 044.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 59 percent open rate. Here's what's happening this week:

  • A pandemic. My plan is to cover coronavirus-related developments only if they impact the future of digital health interventions in some meaningful way. So, this week's edition of E&O will include a few. For example, the crisis has triggered some important regulatory rollbacks that will likely lead to long-term changes -- much more on that after the jump.
  • One quick follow-up to my Sanofi-Verily-Onduo-Dexcom writeup from last week. Verily paid Sanofi $122 million worth of Dexcom stock as a dividend following the restructuring of Onduo, which saw Sanofi's share reduced from 50 percent to 19.9 percent. This is oversimplifying it, but, in effect, Verily paid Sanofi $122 million for 30.1 percent of Onduo.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Recent Articles